Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Olodaterol attenuates bleomycin induced lung fibrosis in mice

Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex
European Respiratory Journal 2016 48: PA5056; DOI: 10.1183/13993003.congress-2016.PA5056
Franziska Herrmann
1Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan-Lutz Wollin
1Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Gantner
2Transl. Medicine and Clin. Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Wex
1Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: The long-acting β2-agonist (LABA) olodaterol was shown to have anti-fibrotic activity in primary human lung fibroblasts (Herrmann et al, Eur Respir J. 2014;44:Suppl.58) however, its anti-fibrotic in vivo efficacy has not yet been demonstrated.

Aim: To test the effect of olodaterol in a mouse model of bleomycin induced lung fibrosis.

Methods: Bleomycin at a dose of 0.5 mg/kg (1.5-2 U/mg) was intratracheally instilled in C57BL/6 mice on day 0. In a preventive (day 1-20) or therapeutic (day 7 -20) treatment regimen mice were exposed once daily for 5 min to an aqueous solution of olodaterol (1 mg/mL) aerosolized with a jet nebulizer. At the end of the study (day 21) lung density was assessed by micro CT analysis and lung function was measured with a FlexiVent system. Bronchoalveolar lavage fluid (BALF) was analyzed for total and differential cell counts and pro-fibrotic cytokines.

Results: The bleomycin challenge induced an increase in lung tissue density, white blood cell (WBC) count and protein concentration in the BAL fluid and a decrease in forced vital capacity (FVC). In the preventive treatment regimen olodaterol attenuated tissue density by 45%, WBC count by 31%, protein by 63% and FVC by 57%. Pro-fibrotic cytokines like TGF-ß or MMP-9 were diminished by 57% and 48%, respectively. Therapeutic treatment with olodaterol attenuated the increase in lung density and the decrease in FVC by 10% and 18%, respectively. WBC accumulation was attenuated by 25% and the increase in total protein, TGF-ß and MMP-9 levels in BALF was inhibited by 43%, 58% and 49%, respectively.

Conclusion: At doses of maximal bronchodilation, olodaterol showed anti-fibrotic properties in a mouse model of bleomycin induced lung fibrosis.

  • Idiopathic pulmonary fibrosis
  • Animal models
  • Bronchodilators
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Olodaterol attenuates bleomycin induced lung fibrosis in mice
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Olodaterol attenuates bleomycin induced lung fibrosis in mice
Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex
European Respiratory Journal Sep 2016, 48 (suppl 60) PA5056; DOI: 10.1183/13993003.congress-2016.PA5056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Olodaterol attenuates bleomycin induced lung fibrosis in mice
Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex
European Respiratory Journal Sep 2016, 48 (suppl 60) PA5056; DOI: 10.1183/13993003.congress-2016.PA5056
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
  • TNFAIP3 (A20) expression is elevated in the sputum of severe asthmatics
  • Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society